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Introduction
Colorectal cancer (CRC) is the second cause of cancer-
related mortality among adult people throughout the 
world (Bush and Haines, 2009; ACS, 2013). It is being 
converted to one of the most complicated challenges of 
human health, particularly in developing countries (Bener, 
2011). It seems along with westernization of life style in 
these countries, such as Iran, CRC will be one of the most 
important leading causes of cancer death among adults in 
the world (Pourhoseingholi et al., 2009). 
Current information shows CRC is the third common 
cancer among Iranian adult males and the forth one among 
the females (excluding skin malignancies) (Mousavi et 
al., 2008; Kolahdoozan et al., 2010). Its incidence has 
been increased during the last 3 decades more than 80% 
according to recent studies (Yazdizadeh et al., 2005; 
Dolatkhah et al., 2015).
Inheritable genetic factors contribute in incidence of 
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Abstract
 Background: Colorectal cancer (CRC) is becoming one of the most complicated challenges of human health, 
particularly in developing countries like Iran. In this paper, we try to characterize CRC cases diagnosed < age 50 
at-risk for Lynch syndrome within central Iran. Materials and Methods: We designed a descriptive retrospective 
study to screen all registered CRC patients within 2000-2013 in Poursina Hakim Research Center (PHRC), a 
referral gastroenterology clinic in central Iran, based on being early-onset (age at diagnosis ≤50 years) and 
Amsterdam II criteria. We calculated frequencies and percentages by SPSS 19 software to describe clinical and 
family history characteristics of patients with early-onset CRC. Results: Overall 1,659 CRC patients were included 
in our study of which 413 (24.9%) were ≤50 years at diagnosis. Of 219/413 successful calls 67 persons (30.6%) 
were reported deceased. Family history was positive for 72/219 probands (32.9%) and 53 families (24.2%) were 
identified as familial colorectal cancer (FCC), with a history of at-least three affected members with any type of 
cancer in the family, of which 85% fulfilled the Amsterdam II Criteria as hereditary non-polyposis colorectal 
cancer (HNPCC) families (45/219 or 20.5%). Finally, 14 families were excluded due to proband tumor tissues 
being unavailable or unwillingness for incorporation. The most common HNPCC-associated extracolonic-
cancer among both males and females of the families was stomach, at respectively 31.8 and 32.7 percent. The 
most common tumor locations among the 31 probands were rectum (32.3%), sigmoid (29.0%), and ascending 
colon (12.9%). Conclusions: Given the high prevalence of FCC (~1/4 of early-onset Iranian CRC patients), it is 
necessary to establish a comprehensive cancer genetic counseling and systematic screening program for early 
detection and to improve cancer prognosis among high risk families. 
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at least 35% of the new cases (Burt, 2007) and hereditary 
non-polyposis colorectal cancer (HNPCC) is the most 
common cause of hereditary CRC (Rybak and Hall, 2011). 
It is an autosomal dominant condition with about 70- 90% 
penetrance due to mutation in the mismatch repair genes 
(Lynch et al., 2009).
Although a prevalence of about 3-5% has been 
estimated for HNPCC in different studies among western 
societies, there is just a little information about the 
prevalence of the disease in Iran (Bavi et al., 2008).
In one study in Tehran hospitals, clinical diagnosis of 
HNPCC was established in 21 (4.7%) probands (Fatemi 
et al., 2010). In a recent study in Isfahan (Central Iran), 
the prevalence was estimated about 2% according to 
Amsterdam II criteria (Nemati et al., 2011). Since no 
screening program has been established for hereditary 
CRC so far in Iranian health system, there is no exact 
epidemiologic data in this area from general population. 
So we designed a new study to set up a screening program 
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for hereditary CRC in Central Iran. In this article we 
discuss some epidemiologic data, obtained from a primary 
screening program based on genetic counseling 
Materials and Methods
We designed a descriptive retrospective study to 
find most detectable samples of HNPCC in central 
Iran, including Isfahan and Chaharmahal va Bakhtyari 
provinces (CMB). Our samples included 1659 CRC 
patients registered in cancer registry unit of Isfahan 
Provincial Health Center or referred to Poursina Hakim 
Clinic (PHRC), a famous referral gastroenterology 
clinic in central Iran, from 2000 to end of 2013. As the 
population-based cancer registry has been set up in our 
region since 2006, apparently our study does not cover 
all CRC patients in Central Iran.
We used being early-onset disease (age at diagnosis ≤50 
years) and Amsterdam II criteria, consecutively, to primary 
selection of our samples. This stringent screening method 
was selected due to our financial limitations. Amsterdam 
II criteria include: having at least 3 affected members 
with one of the HNPCC-associated cancers (CRC, other 
GI cancers, endometrial, renal, breast (according to some 
resources), Brain, Skin, and pelvic cancers) in at least two 
successive generations, and one of these three members 
being a first degree relative of the other two and at least one 
diagnosed before the age of 50 years. So, we reviewed at 
first the patients’ rolls and selected all probands with age 
up to 50 years to call and ask them about family history 
of cancer. Then all patients with positive family history 
of cancer and/or their families were invited for genetic 
counseling and face to face interview. We considered any 
kind of cancer in addition of HNPCC-associated cancers. 
The pedigrees were confirmed by interviewing at least 
2-3 members of family. We also requested all clinical and 
paraclinical documents to verify reported malignancies in 
the probands and their relatives, if were available. Finally, 
the obtained data was statistically analyzed by SPSS 19 
software package (SPSS Inc., Chicago, IL, USA).
Results 
We found that 413/1659 (24.9%) of the patients had 
been affected by early-onset CRC (age at the time of 
diagnosis ≤50). In addition, 213/413 (51.6%) of these 
probands were male.
Our response rate in follow up was 219/413 (53%) of 
which in 67/219 (30.6%) the probands had been deceased 
and their first-degree relatives were responded on behalf 
of them. Family history was positive for 72/219 probands 
(32.9%) and among them, we found 53 families (24.2%) 
with at least three affected members to have any different 
types of cancer. We classified them as “Familial Colorectal 
Cancer” (FCC) families. 
Overall, 45/53 (85%) of FCC families fulfilled the 
Amsterdam II Criteria as HNPCC families (45/219 or 
20.5% of all CRC cases). Though we invited all of them 
Table 1. Frequency of All Cancer Sites in the HNPCC Families in Both Male and Female Patients
tumor site
sex
Totalmale female
frequency percent frequency percent
colorectal cancer 38 36.5 30 36.1 68
lung cancer 16 15.4 1 1.2 17
gastric cancer 14 13.5 17 20.5 31
small bowel cancer 7 6.7 2 2.4 9
prostate cancer 6 5.8 6
brain cancer 5 4.8 6 7.2 11
hematopoietic 
cancer 5 4.8 3 3.6 8
hepatobiliary 
cancer 3 2.9 3 3.6 6
bladder 2 1.9 1 1.2 3
testis cancer 2 1.9 2
thyroid cancer 2 1.9 0 0 2
renal cancer 1 1 0 0 1
skin cancer 1 1 1 1.2 2
bone cancer 1 1 1 1.2 2
pancreas cancer 1 1 0 0 1
breast cancer 12 14.5 12
uterus cancer 5 6 5
nasopharynx 0 0 1 1.2 1
Total 104 100 83 100 187
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for genetic testing, just 31/45 (69%) of them were finally 
included in the next molecular testing stages. Of 14 
excluded families, 10 families were omitted because their 
probands’ tumor tissues were unavailable, and 4 others 
were excluded due to reluctance for incorporation. 
Altogether, 31 HNPCC families had 187 cancer 
patients including 168 HNPCC-associated cancers, with 
3-13 affected members in each family, so the affected 
members in the families were averagely 5.9. Extracolonic 
cancers were more prevalent among males (M/F=1.3).
Of 31 probands, 16 cases (51.6%) had one parents 
affected with CRC, 3 had 2 parents affected (9.7%), and 
8 in at least one sibling (25.8%). 
The most common cancers in male HNPCC families 
were: CRC (36.5%), lung (15.4%), stomach (13.5%), 
small bowel (6.7%), and prostate (5.8%); while in females: 
CRC (36.1%), stomach (20.5%), breast (14.5%), brain 
(7.2%), and uterus (6%). Of these, stomach with 31.8 
and 32.7 percent among males and females, respectively, 
was the most frequent affected site in HNPCC-associated 
extracolonic cancers (Table 1,2).
Although, average age at diagnosis in HNPCC 
probands was 41.3 (range 24-50 years), it was 50.6 
(range 2-82 years) for all cancers within 31 HNPCC 
families. The least average age at diagnosis was related 
to thyroid, brain, and bone cancers with 16.5, 38.5, and 
39.5 years, respectively. While, average age at diagnosis 
of prostate, pancreas, and lung cancers were 70.2, 70, and 
66, respectively. In addition, average age of CRC diagnosis 
in the families was 48.7. 
12/31 (38.7%) of the HNPCC probands, and 120/187 
(64.2%) of the all affected members had been deceased. 
The mean survival length in the HNPCC probands was 
8.0 years (range 1-33). It was 5.8 years (range 1-25) in the 
deceased and 9.4 years (range 2-33) in the live probands 
after initial clinical diagnosis. 
The frequency of tumor pathological stage in which 
the HNPCC probands had been identified, according 
to TNM staging system, included: 1/31 (3.2%) stage 
I, 10/31 (32.3%) stage II, 10/31 (32.3%) stage III, and 
10/31 (32.3%) stage IV. Of the live probands, 9/19 
(47.4%) were in stage III or IV at diagnosis, while for 
the deceased probands, it was 11/12 (91.7%). Survival 
period, distance between age at diagnosis and death, was 
10, 4.7, and 2.3 years in deceased probands identified 
at stage I, III, and IV, respectively. According to tumor 
pathological reports of the probands, the most common 
diagnosis had been reported as “well differentiated 
adenocarcinoma” by 38.7%, and the least one was “non-
mucinous adenocarcinoma” by 3.2%. 
The most common tumor locations among the 31 
probands were respectively: rectum (32.3%), sigmoid 
(29.0%), and ascending colon (12.9%). (Table 3)
Table 3. Frequency of Tumor Locations in HNPCC 
Probands 
tumor location Frequency Percent
ascending colon 4 12.9
transverse colon 1 3.2
descending colon 2 6.5
sigmoid colon 9 29
rectum 10 32.3
cecum 4 12.9
unknown 1 3.2
Total 31 100
Table 2. Frequency of HNPCC-Associated Extracolonic Cancer Sites in the HNPCC Families in Both Male and 
Female Patients
tumor site
sex
male female
frequency percent frequency percent
gastric cancer 14 31.8 17 32.7
small bowel cancer 7 15.9 2 3.8
brain cancer 5 11.4 6 11.5
hematopoietic cancer 5 11.4 3 5.8
hepatobiliary cancer 3 6.8 3 5.8
bladder 2 4.5 1 1.9
testis cancer 2 4.5
thyroid cancer 2 4.5 0 0
renal cancer 1 2.3 0 0
skin cancer 1 2.3 1 1.9
bone cancer 1 2.3 1 1.9
pancreas cancer 1 2.3 0 0
breast cancer 12 23.1
uterus cancer 5 9.6
nasopharynx 0 0 1 1.9
Total 44 100 52 100
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Discussion
I- Epidemiologic features: This study was designed 
to find most detectable HNPCC families in Central 
Iran, since there is a lack of data around the issue in our 
population. Due to our financial limitations and high 
family size in Iranian population, we used Amsterdam 
II Criteria as a more specific tool than revised Bethesda 
guidelines to screen the early-onset at-risk patients (Syngal 
et al., 2000; Pinol et al., 2005).
In spite of our repeated attempts, we did not succeed 
to find about 47% of probands. It is due to changing of 
the patients’ phone numbers and addresses after passing 
too much time.
Overall, 213/413 (51.6%) of the probands with age up 
to 50 years were male. It is similar to the gender structure 
of our population, so 51% of the population throughout 
the Province was male according to 2011 census (on-line 
available in: www.sci.org.ir). Although CRC incidence 
rates among most populations are significantly higher 
in males than in females, there are more differences 
between Western males and females in these rates than 
Eastern populations. So, age-standardized CRC incidence 
rate, during 2008, among males and females in Western 
European population have been 41.2 and 26.3, and in 
Western Asian populations 13.1 and 10.1, respectively 
(Jemal et al., 2011). Apparently, the incidence rate of 
CRC, particularly in early-onset group, is similar in both 
male and female among our population according to our 
results and some similar studies (Kolahdoozan et al., 2010; 
Dolatkhah et al., 2015).
Average age of the HNPCC probands at diagnosis in 
our population was a bit less than the Western population. 
This study among other Eastern studies has shown that 
Early-onset CRC (less than 50 years of age at diagnosis) 
covers almost one fourth of all CRC cases in the country. 
This is different from Western countries where the rates 
of early-onset CRC include less than 10% of all CRC 
cases (Griffin et al., 1991; Mitry et al., 2001; Yuen et al., 
2002; Claes et al., 2005; Yazdizadeh et al., 2005; Ansari 
et al., 2006; Dolatkhah et al., 2015). Given the changing 
of life style in developing societies like Iran toward 
westernization, in particular within youth, incident rate of 
early-onset CRC has been increased in these populations 
during the recent decades (Fatemi et al., 2010; Safari et 
al., 2013; Dolatkhah et al., 2015).
II- Clinicopathologic features: Prevalence of the FCC 
and HNPCC families 33% of our probands had a positive 
family history of cancer among their first or second 
degree relatives. This is near to other previous studies 
in Iran (Fatemi et al., 2010; Dolatkhah et al., 2015). 
We considered for FCC families, existence of at least 
three affected members among the first or second degree 
relatives. Accordingly, the frequency rate of FCC among 
the early-onset probands in our study was calculated 
24.2%, most of which fulfilled the Amsterdam II Criteria 
and were reproduced as HNPCC families (20.5%). It is 
more than previous studies in the Province and other parts 
of Iran (Yuen et al., 2002; Ansari et al., 2006; Fatemi et al., 
2010; Nemati et al., 2011; Dolatkhah et al., 2015). Since 
the proportion of early-onset probands to all CRC patients 
has been calculated nearly 25%, the total frequency of 
HNPCC families according to Amsterdam II Criteria is 
estimated 0.25×20.5% = 5.1%. However, a portion of 
the patients older than 50 years are likely related to other 
unknown HNPCC families which are missed in our study 
(Jasperson et al., 2010; Nemati et al., 2011). Therefore, it 
seems the previous report of HNPCC frequency in Isfahan 
(2%) had been underestimated (Nemati et al., 2011). 
Meanwhile, given the limitation of our study to not include 
all CRC cases, a precise estimation of HNPCC prevalence 
could be impossible. On the other hand, according to the 
last WHO report about life expectancy (LE) in worldwide 
countries, LE in Iran was averagely estimated 73.5 years 
for 2012 which was 2.5 years more than world average 
(WHO, 2012). Meanwhile, it was about 6.5 years less than 
the most Western countries. Apparently it could justify 
the relative high proportion of early-onset CRC patients 
among Iranian populations. 
According to our results, more than 74% of Amsterdam 
II positive probands had no cancer affected siblings, 
and there was no cancer history among the parents of 
about 50%. It shows the importance of complete genetic 
counseling covering at least three generations of every 
pedigree (Maserat et al., 2009). A significant portion of 
these families would be likely excluded from the Lynch
Syndrome after molecular analyses. These cases are 
usually associated to other hereditary cancer syndromes, a 
fact that has been confirmed by different studies (Lindor, 
2009; Francisco et al., 2011; Dominguez-Valentin et al., 
2015).
Colonic and extracolonic malignancies: CRC was the 
most common cancer among HNPCC families by nearly 
36%, compatible with other studies in Iran (Ansari et al., 
2006; Fatemi et al., 2010; Dolatkhah et al., 2015), but it is 
much less than another recent study (Nemati et al., 2011). 
Meanwhile, there are significant discrepancies, 33-78%, 
between similar studies in other countries (Park et al., 
2000; Maul et al., 2006; da Silva et al., 2010; Bansidhar, 
2012).
Also we found gastric cancer (GC) as the most 
common HNPCC-associated extracolonic cancer by 31.8 
and 32.7 percent among males and females, respectively, 
as it is confirmed by others (Fatemi et al., 2010; Nemati 
et al., 2011). There are, however, distinct discrepancies 
between Western and Eastern populations over this issue 
(Bansidhar, 2012). In a Brazilian study, GC was the second 
most common extracolonic cancer in HNPCC families 
(da Silva et al., 2010). In addition, several Chinese and 
Korean studies have presented GC as the most common 
extracolonic cancer in HNPCC (Park et al., 2000), while in 
Western populations, the prevalence of GC within HNPCC 
cohorts is the third or fourth most common cancer (Maul 
et al., 2006; Bansidhar, 2012). These discrepancies could 
be related to environmental factors (Vasen et al., 2013). 
We also found the lung cancer as the second common 
cancer after CRC in males (15.4%), among HNPCC 
families. Although, some authors, in 1990s decade, 
believed that having HNPCC could even protect the 
patients against some other malignancies such as lung 
(Lynch and Chapelle, 1999), some recent studies have 
shown new presentations of HNPCC and Lynch syndrome 
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by which our understanding is evolving (Vasen et al., 
2013; Steinke et al., 2013). Meanwhile, environmental 
conditions have significant role in familial clustering of 
lung cancer (Sun et al., 2007; Brennan et al., 2011), So it 
might be an interaction between both environmental and 
genetic factors causes an increase in the incidence the lung 
cancer (Brennan et al., 2011; Peto, 2001).
Amazingly, the frequency of uterus cancer among 
female members of the HNPCC families has been less 
than our prediction according to the previous studies 
(Park et al., 2000; Maul et al., 2006; Pickhardt et al., 2010; 
Vasen et al., 2013). It may be due to some specific genetic 
characteristics of our populations about which more future 
researches would be helpful. 
Given the results, the average age of cancer diagnosis 
in some organs such as prostate, pancreas, and lung within 
the HNPCC families have been near to its rate among 
general population (Sadjadiet al., 2007; Mousavi et al., 
2009). Apparently, in these types of cancers environmental 
and senile factors are dominant, and inheritable genetic 
factors have likely a little effect to trigger them (Yoder, 
2006; Kratzke and Franklin, 2012).
Tumor sites in HNPCC probands: Although right colon 
has been the most common involved site in CRC patients 
of HNPCC families, particularly among early-onset of 
them (Lynch et al., 2009; Nemati et al., 2011), in a recent 
Iranian study, just 35.4% of CRC patients with positive 
family history had a tumor in right colon (Fatemi et al., 
2010). In our study, right colon was the third common sites 
after rectum and sigmoid colon, being only 26% of CRC 
tumors. Future studies could elucidate more information 
in all parts of Iran.
Survival and mortality rates: Over 13 years cancer 
registering in PHRC convinces us that more than one third 
(39%) of our HNPCC probands have deceased during this 
period. According to different studies, 5-year survival of 
HNPCC probands has been estimated 55-94% in various 
populations (Stigliano et al., 2008; Haghighi et al., 2009). 
It was 82.5% in HNPCC-CRC patients versus 56.4% in 
sporadic ones according to one study in Iran (Haghighi 
et al., 2009). HNPCC-CRC probands in our study lived 
averagely 8.0 years after the first diagnosis. Meanwhile, 
only 35.5% of them had been clinically identified in TNM 
stage I or II .Since advanced pathologic stage at diagnosis 
time is due to diagnostic delays (Mitchell et al., 2008), we 
expect to identify the patients in more advanced pathologic 
stage in Iran than most developed countries according 
to lack of a systematic program for cancer screening 
in Iranian Health System leading to worse prognosis 
(Cappell, 2008). Therefore, establishing a systematic 
screening program to early detection of CRC, particularly 
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